Evropská unie - čeština - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastická činidla - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq jako monoterapie je indikován k léčbě dospělých pacientů s lokálně pokročilým nebo metastazujícím nemalobuněčným karcinomem plic po předchozí chemoterapii. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq jako monoterapie je indikován k léčbě dospělých pacientů s lokálně pokročilým nebo metastazujícím nemalobuněčným karcinomem plic po předchozí chemoterapii. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Evropská unie - čeština - EMA (European Medicines Agency)

bayer ag - sorafenib - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastická činidla - hepatocelulární carcinomanexavar je indikován k léčbě hepatocelulárního karcinomu. renální buňky carcinomanexavar je indikován k léčbě pacientů s pokročilým renálním karcinomem, u kterých selhala předchozí léčba interferonem-alfa nebo interleukinu-2 na terapii, nebo jsou považovány za nevhodné pro takové terapie. diferencované štítné žlázy carcinomanexavar je indikován pro léčbu pacientů s progresivním, lokálně pokročilým nebo metastatickým, diferencovaný (papilární/folikulární/z hürthleho buněk) karcinomem štítné žlázy, žáruvzdorné do radioaktivního jódu.

Evropská unie - čeština - EMA (European Medicines Agency)

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastická činidla - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

gedeon richter plc., budapešť maĎarsko - 17664 sorafenib-tosilÁt - potahovaná tableta - 200mg - sorafenib

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

pharmagen cz s.r.o., praha array - 17664 sorafenib-tosilÁt - potahovaná tableta - 200mg - sorafenib

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

sandoz s.r.o., praha array - 17664 sorafenib-tosilÁt - potahovaná tableta - 200mg - sorafenib

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

sandoz s.r.o., praha array - 17664 sorafenib-tosilÁt - potahovaná tableta - 400mg - sorafenib

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

stada arzneimittel ag, bad vilbel array - 17664 sorafenib-tosilÁt - potahovaná tableta - 200mg - sorafenib

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

stada arzneimittel ag, bad vilbel array - 17664 sorafenib-tosilÁt - potahovaná tableta - 400mg - sorafenib

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

teva pharmaceuticals cr, s.r.o., praha array - 17664 sorafenib-tosilÁt - potahovaná tableta - 200mg - sorafenib